{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:12:25Z","timestamp":1782958345352,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41375-025-02589-4","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T13:46:36Z","timestamp":1743774396000},"page":"1351-1361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CircTADA2A stabilizes p53 via interacting with TRIM28 and suppresses the maintenance of FLT3-ITD acute myeloid leukemia"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1526-0182","authenticated-orcid":false,"given":"Ran","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shishuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengke","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9931-4055","authenticated-orcid":false,"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1338-8764","authenticated-orcid":false,"given":"Junmin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"2589_CR1","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM, Daver NG, Altman JK, Stein EM, et al. Acute myeloid leukemia management and research in 2025. CA Cancer J Clin. 2024;75:46\u201367.","DOI":"10.3322\/caac.21873"},{"key":"2589_CR2","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1200\/JCO.22.00715","volume":"41","author":"T Grob","year":"2023","unstructured":"Grob T, Sanders MA, Vonk CM, Kavelaars FG, Rijken M, Hanekamp DW, et al. Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia. J Clin Oncol. 2023;41:756\u201365.","journal-title":"J Clin Oncol"},{"key":"2589_CR3","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s40265-017-0779-0","volume":"77","author":"ES Kim","year":"2017","unstructured":"Kim ES. Midostaurin: First Global Approval. Drugs. 2017;77:1251\u20139.","journal-title":"Drugs"},{"key":"2589_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"2589_CR5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2589_CR6","doi-asserted-by":"publisher","first-page":"104424","DOI":"10.1016\/j.critrevonc.2024.104424","volume":"201","author":"M Ruglioni","year":"2024","unstructured":"Ruglioni M, Crucitta S, Luculli GI, Tancredi G, Del Giudice ML, Mechelli S, et al. Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy. Crit Rev Oncol Hematol. 2024;201:104424.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2589_CR7","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","volume":"20","author":"M Winkle","year":"2021","unstructured":"Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics - challenges and potential solutions. Nat Rev Drug Discov. 2021;20:629\u201351.","journal-title":"Nat Rev Drug Discov"},{"key":"2589_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-024-00943-2","volume":"23","author":"JR Androsavich","year":"2024","unstructured":"Androsavich JR. Frameworks for transformational breakthroughs in RNA-based medicines. Nat Rev Drug Discov. 2024;23:421\u201344.","journal-title":"Nat Rev Drug Discov"},{"key":"2589_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41587-024-02204-4","volume":"43","author":"SK Guo","year":"2025","unstructured":"Guo SK, Liu CX, Xu YF, Wang X, Nan F, Huang Y, et al. Therapeutic application of circular RNA aptamers in a mouse model of psoriasis. Nat Biotechnol. 2025;43:236\u201346.","journal-title":"Nat Biotechnol"},{"key":"2589_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jconrel.2022.05.043","volume":"348","author":"X Liu","year":"2022","unstructured":"Liu X, Zhang Y, Zhou S, Dain L, Mei L, Zhu G. Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines. J Control Release. 2022;348:84\u201394.","journal-title":"J Control Release"},{"key":"2589_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41571-021-00585-y","volume":"19","author":"LS Kristensen","year":"2022","unstructured":"Kristensen LS, Jakobsen T, Hager H, Kjems J. The emerging roles of circRNAs in cancer and oncology. Nature Rev Clin Oncol. 2022;19:188\u2013206.","journal-title":"Nature Rev Clin Oncol"},{"key":"2589_CR12","doi-asserted-by":"publisher","first-page":"148019","DOI":"10.1016\/j.gene.2023.148019","volume":"895","author":"B Yang","year":"2024","unstructured":"Yang B, Wang YW, Zhang K. Interactions between circRNA and protein in breast cancer. Gene. 2024;895:148019.","journal-title":"Gene"},{"key":"2589_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12943-021-01446-z","volume":"20","author":"V Singh","year":"2021","unstructured":"Singh V, Uddin MH, Zonder JA, Azmi AS, Balasubramanian SK. Circular RNAs in acute myeloid leukemia. Molecular cancer. 2021;20:149.","journal-title":"Molecular cancer"},{"key":"2589_CR14","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1161\/CIRCRESAHA.119.316061","volume":"127","author":"D Han","year":"2020","unstructured":"Han D, Wang Y, Wang Y, Dai X, Zhou T, Chen J, et al. The Tumor-Suppressive Human Circular RNA CircITCH Sponges miR-330-5p to Ameliorate Doxorubicin-Induced Cardiotoxicity Through Upregulating SIRT6, Survivin, and SERCA2a. Circ Res. 2020;127:e108\u2013e125.","journal-title":"Circ Res"},{"key":"2589_CR15","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.molcel.2010.08.029","volume":"39","author":"JM Doyle","year":"2010","unstructured":"Doyle JM, Gao J, Wang J, Yang M, Potts PR. MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Molecular cell. 2010;39:963\u201374.","journal-title":"Molecular cell"},{"key":"2589_CR16","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/sj.emboj.7600791","volume":"24","author":"C Wang","year":"2005","unstructured":"Wang C, Ivanov A, Chen L, Fredericks WJ, Seto E, Rauscher FJ 3rd, et al. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. Embo j. 2005;24:3279\u201390.","journal-title":"Embo j"},{"key":"2589_CR17","doi-asserted-by":"publisher","first-page":"922675","DOI":"10.3389\/fcell.2022.922675","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu Y, Cao B, Hu L, Ye J, Tian W, He X. The Dual Roles of MAGE-C2 in p53 Ubiquitination and Cell Proliferation Through E3 Ligases MDM2 and TRIM28. Front Cell Develop Biol. 2022;10:922675.","journal-title":"Front Cell Develop Biol"},{"key":"2589_CR18","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1021\/jm501092z","volume":"58","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Aguilar A, Bernard D, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. J Med Chem. 2015;58:1038\u201352.","journal-title":"J Med Chem"},{"key":"2589_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","volume":"20","author":"AJ Levine","year":"2020","unstructured":"Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020;20:471\u201380.","journal-title":"Nat Rev Cancer"},{"key":"2589_CR20","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1182\/blood.2019003538","volume":"135","author":"J Long","year":"2020","unstructured":"Long J, Jia MY, Fang WY, Chen XJ, Mu LL, Wang ZY, et al. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia. Blood. 2020;135:1472\u201383.","journal-title":"Blood"},{"key":"2589_CR21","doi-asserted-by":"publisher","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","volume":"15","author":"KJ Kauffman","year":"2015","unstructured":"Kauffman KJ, Dorkin JR, Yang JH, Heartlein MW, DeRosa F, Mir FF, et al. Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs. Nano Lett. 2015;15:7300\u20136.","journal-title":"Nano Lett"},{"key":"2589_CR22","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","volume":"185","author":"L Qu","year":"2022","unstructured":"Qu L, Yi Z, Shen Y, Lin L, Chen F, Xu Y, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022;185:1728\u20131744.e1716.","journal-title":"Cell"},{"key":"2589_CR23","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","volume":"9","author":"RA Wesselhoeft","year":"2018","unstructured":"Wesselhoeft RA, Kowalski PS, Anderson DG. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat Commun. 2018;9:2629.","journal-title":"Nat Commun"},{"key":"2589_CR24","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","volume":"42","author":"Y Liu","year":"2024","unstructured":"Liu Y, Su Z, Tavana O, Gu W. Understanding the complexity of p53 in a new era of tumor suppression. Cancer cell. 2024;42:946\u201367.","journal-title":"Cancer cell"},{"key":"2589_CR25","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41568-023-00658-3","volume":"24","author":"S Peuget","year":"2024","unstructured":"Peuget S, Zhou X, Selivanova G. Translating p53-based therapies for cancer into the clinic. Nat Rev Cancer. 2024;24:192\u2013215.","journal-title":"Nat Rev Cancer"},{"key":"2589_CR26","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41568-024-00721-7","volume":"24","author":"VM Conn","year":"2024","unstructured":"Conn VM, Chinnaiyan AM, Conn SJ. Circular RNA in cancer. Nat Rev Cancer. 2024;24:597\u2013613.","journal-title":"Nat Rev Cancer"},{"key":"2589_CR27","doi-asserted-by":"publisher","first-page":"e2300489120","DOI":"10.1073\/pnas.2300489120","volume":"120","author":"L Ginn","year":"2023","unstructured":"Ginn L, Maltas J, Baker MJ, Chaturvedi A, Wilson L, Guilbert R, et al. A TIAM1-TRIM28 complex mediates epigenetic silencing of protocadherins to promote migration of lung cancer cells. Proc Natl Acad Sci USA. 2023;120:e2300489120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2589_CR28","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.7150\/jca.95876","volume":"15","author":"D Li","year":"2024","unstructured":"Li D, Cheng J, Zhang W, Zhang L, Maghsoudloo M, Fu J, et al. Tripartite motif-containing 28 (TRIM28) expression and cordycepin inhibition in progression, prognosis, and therapeutics of patients with breast invasive carcinoma. J Cancer. 2024;15:4374\u201385.","journal-title":"J Cancer"},{"key":"2589_CR29","first-page":"1860","volume":"39","author":"F Li","year":"2018","unstructured":"Li F, Wang Z, Lu G. TRIM28 promotes cervical cancer growth through the mTOR signaling pathway. Oncol Rep. 2018;39:1860\u20136.","journal-title":"Oncol Rep"},{"key":"2589_CR30","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.7150\/jca.86742","volume":"14","author":"Z Shang","year":"2023","unstructured":"Shang Z, Wu X, Zheng S, Wei Y, Hong Z, Ye D. A systematic pan-cancer analysis identifies TRIM28 as an immunological and prognostic predictor and involved in immunotherapy resistance. J Cancer. 2023;14:2798\u2013810.","journal-title":"J Cancer"},{"key":"2589_CR31","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.3390\/cells9112493","volume":"9","author":"S Scholl","year":"2020","unstructured":"Scholl S, Fleischmann M, Schnetzke U, Heidel FH. Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments. Cells. 2020;9:2493.","journal-title":"Cells"},{"key":"2589_CR32","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562:526\u201331.","journal-title":"Nature"},{"key":"2589_CR33","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1182\/blood-2017-02-763086","volume":"130","author":"M Prokocimer","year":"2017","unstructured":"Prokocimer M, Molchadsky A, Rotter V. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. Blood. 2017;130:699\u2013712.","journal-title":"Blood"},{"key":"2589_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2013-11-538819","volume":"124","author":"D Sasca","year":"2014","unstructured":"Sasca D, H\u00e4hnel PS, Szybinski J, Khawaja K, Kriege O, Pante SV, et al. SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. Blood. 2014;124:121\u201333.","journal-title":"Blood"},{"key":"2589_CR35","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1182\/bloodadvances.2021005867","volume":"6","author":"N Maslah","year":"2022","unstructured":"Maslah N, Verger E, Giraudier S, Chea M, Hoffman R, Mascarenhas J, et al. Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition. Blood Adv. 2022;6:2813\u201323.","journal-title":"Blood Adv"},{"key":"2589_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41698-025-00823-x","volume":"9","author":"V Khanna","year":"2025","unstructured":"Khanna V, Eslami G, Reyes R, Diep R, Fernandez-Pol S, Stehr H, et al. MDM2 inhibition is associated with the emergence of TP53-altered clonal hematopoiesis. NPJ Precis Oncol. 2025;9:34.","journal-title":"NPJ Precis Oncol"},{"key":"2589_CR37","doi-asserted-by":"crossref","unstructured":"RNA-based therapies. Nat Biotechnol. 2023;41:1071.","DOI":"10.1038\/s41587-023-01885-7"},{"key":"2589_CR38","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1093\/nar\/gkv045","volume":"43","author":"S Petkovic","year":"2015","unstructured":"Petkovic S, M\u00fcller S. RNA circularization strategies in vivo and in vitro. Nucleic Acids Res. 2015;43:2454\u201365.","journal-title":"Nucleic Acids Res"},{"key":"2589_CR39","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1186\/s12951-024-02972-w","volume":"22","author":"E Haghighi","year":"2024","unstructured":"Haghighi E, Abolmaali SS, Dehshahri A, Mousavi Shaegh SA, Azarpira N, Tamaddon AM. Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach. J Nanobiotechnol. 2024;22:710.","journal-title":"J Nanobiotechnol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02589-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02589-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02589-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T11:04:56Z","timestamp":1748948696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02589-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2589"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02589-4","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board from Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine and research was conducted in accordance with the Declaration of Helsinki. All patients provided informed consent. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}